Phosphatidylinositol 3-Kinases
"Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell.
| Descriptor ID |
D019869
|
| MeSH Number(s) |
D08.811.913.696.620.500
|
| Concept/Terms |
Phosphatidylinositol 3-Kinases- Phosphatidylinositol 3-Kinases
- Phosphatidylinositol 3 Kinases
- Phosphoinositide 3-Hydroxykinase
- PI 3-Kinase
- PtdIns 3-Kinases
- 3-Kinases, PtdIns
- PtdIns 3 Kinases
- PI-3K
- PI3 Kinases
- Kinases, PI3
- PI3-Kinase
- PtdIns 3-Kinase
- Phosphatidylinositol-3-OH Kinase
- PI-3 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 5 | 5 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 3 | 4 |
| 2000 | 4 | 6 | 10 |
| 2001 | 4 | 6 | 10 |
| 2002 | 3 | 6 | 9 |
| 2003 | 8 | 5 | 13 |
| 2004 | 4 | 2 | 6 |
| 2005 | 7 | 2 | 9 |
| 2006 | 2 | 5 | 7 |
| 2007 | 0 | 5 | 5 |
| 2008 | 3 | 6 | 9 |
| 2009 | 4 | 7 | 11 |
| 2010 | 4 | 6 | 10 |
| 2011 | 2 | 6 | 8 |
| 2012 | 1 | 10 | 11 |
| 2013 | 1 | 9 | 10 |
| 2014 | 5 | 9 | 14 |
| 2015 | 5 | 5 | 10 |
| 2016 | 1 | 9 | 10 |
| 2017 | 1 | 3 | 4 |
| 2018 | 1 | 3 | 4 |
| 2019 | 2 | 3 | 5 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 7 | 7 |
| 2023 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphatidylinositol 3-Kinases" by people in Profiles.
-
ASO Visual Abstract: PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence for Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Ann Surg Oncol. 2023 05; 30(5):3123-3124.
-
Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells. Oncogene. 2023 03; 42(12):881-893.
-
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 Jun; 18(3):41-55.
-
PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Ann Surg Oncol. 2023 May; 30(5):3114-3122.
-
Transcriptional Dysregulation Underlies Both Monogenic Arrhythmia Syndrome and Common Modifiers of Cardiac Repolarization. Circulation. 2023 Mar 07; 147(10):824-840.
-
Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors. Mod Pathol. 2022 11; 35(11):1684-1694.
-
Muscone suppresses myocardial ischemia damage by regulating PI3K/Akt signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2022 12 01; 1868(12):166539.
-
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
-
Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care. Brain. 2022 04 29; 145(3):925-938.
-
Intermittent glucocorticoid treatment enhances skeletal muscle performance through sexually dimorphic mechanisms. J Clin Invest. 2022 03 15; 132(6).